Older adults and those with a worse thyroid eye disease clinical activity score at baseline were less likely to respond to glucocorticoid therapy, according to findings published in Thyroid.
“The leading position of intravenous glucocorticoids as the first-line treatment for moderate to severe Graves’ orbitopathy in many countries worldwide, due to its availability and low cost, is being challenged by the new immunotherapies,” Maria-Cristina Burlacu, MD, deputy head of clinic in the department of endocrinology and nutrition at Cliniques Universitaires Saint-Luc, Université